The Innovative Health Initiative (IHI) –
Europe's largest public-private initiative

The Innovative Health Initiative (IHI), formerly called Innovative Medicines Initiative (IMI), is an initiative aiming to make the European Union’s pharmaceutical research facilities more competitive. Competing industrial and research companies are working together to speed up the development of better and safer medicines as well as new therapeutic approaches for patients. The initial IMI initiative was part of the EU’s Seventh Framework Programme for Research (FP7), was continued as IMI2 within the Horizon 2020 programme, and since December 2021, is now called IHI within the new Horizon Europe programme. The overall budget for IHI is 2.4 billion Euros (2021 – 2027).

concentris also manages IHI / IMI projects and has ample experience (see our current IMI projects).

Sources and more information: